Krystal Biotech Reports Q2 2026: VYJUVEK Revenue Hits $119.2M, Pipeline Advances with Multiple Readouts Ahead
KRYS has more than doubled off its 52-week low of $130.5.
Summary
Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2 million, net income of $54.8 million, and a $1.1 billion cash position. The company guided FY 2026 non-GAAP R&D and SG&A expenses to $175–$195 million and highlighted multiple clinical data readouts expected in 2H 2026.
Key Events · Earnings and Guidance · KRYS
-
VYJUVEK Revenue Growth
Global VYJUVEK net product revenue reached $119.2 million in Q2 2026, a 24% increase over Q2 2025, with a 95% gross margin. Cumulative revenue since launch now totals $965.9 million.
-
Strong Profitability and Cash Position
Net income was $54.8 million ($1.85 basic EPS) for Q2 2026, up from $38.3 million a year ago. Cash, equivalents, and investments totaled $1.1 billion as of June 30, 2026.
-
FY 2026 Expense Guidance
The company guided full-year 2026 non-GAAP R&D and SG&A expenses to $175–$195 million, excluding stock-based compensation, indicating controlled spending while advancing the pipeline.
-
Multiple Clinical Catalysts in 2H 2026
Top-line data from the IOLITE study of KB803 for DEB corneal abrasions is expected in Q4 2026. Interim results from the KB407 cystic fibrosis study and an update on intratumoral KB707 in Gorlin syndrome are also anticipated before year-end.
Analysis · KRYS · Life Sciences
Krystal Biotech delivered strong Q2 2026 results with VYJUVEK global revenue reaching $119.2 million, a 24% year-over-year increase, and net income of $54.8 million. The company ended the quarter with $1.1 billion in cash and investments, providing ample runway to advance a deep pipeline. Multiple clinical catalysts are expected in the second half of 2026, including top-line data from the IOLITE study of KB803 in DEB corneal abrasions and interim results from the KB407 cystic fibrosis program. The company also provided FY 2026 non-GAAP R&D and SG&A expense guidance of $175–$195 million, signaling disciplined spending. With VYJUVEK launches in Spain and Italy on track for later this year and a growing prescriber base, the commercial foundation continues to strengthen. The combination of robust financials, a clear pipeline roadmap, and near-term data readouts makes this a notable update for investors.
At the time of this filing, KRYS was trading at $315.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $130.50 to $382.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.